Recent Additions

Thu, Jan 23, 2020 - 17:27
The National Viral Hepatitis Roundtable (NVHR), a national coalition working to eliminate viral hepatitis, today applauded the National Academies of Sciences, Engineering, and Medicine (NASEM), for its report analyzing the simultaneous opioid use disorder (OUD) and infectious disease epidemics in the U.S. and calling for a congressionally funded, integrated approach to addressing the epidemics.
Thu, Nov 07, 2019 - 09:58
NVHR and public health experts will provide an update to the latest “Hepatitis C: State of Medicaid Access” report during a panel discussion on Monday, November 11.
Wed, Oct 09, 2019 - 16:32
WASHINGTON, DC & BOSTON, MA (Oct. 10, 2019) – The National Viral Hepatitis Roundtable (NVHR) and the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) today launched an update to “Hepatitis C: State of Medicaid Access,” an interactive project grading all 50 state Medicaid programs, as well as the District of Columbia and Puerto Rico, according to access to curative treatments for hepatitis C, the nation’s deadliest infectious disease. NVHR, Harvard and other leading viral hepatitis advocates today also sent a letter to the U.S. Centers for Medicare and Medicaid Services (CMS) urging the agency to take action to end discriminatory state treatment restrictions, which, according to CMS guidance, violate federal Medicaid law.
Wed, Oct 09, 2019 - 13:58
Please join the National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation at Harvard University to urge the Centers for Medicare and Medicaid Services to address illegal hepatitis C treatment prior authorization criteria in state Medicaid programs.
Tue, Sep 10, 2019 - 15:15
Atlanta, GA: On September 10th, 2019 the U.S. Centers for Disease Control and Prevention (CDC) released official viral hepatitis surveillance data for the year 2017. The major takeaway from the report is that the United States experienced increases in cases of hepatitis A, hepatitis B, and hepatitis C, which were predominantly attributable to unsafe injection drug use, and lack of vaccine protection among adults at risk for hepatitis A and B infection.